.png?quality=75)
Artificial Intelligence
A Promising Step Forward for Predicting Lung Cancer From Google
PR-M05-19-NI-077May 28, 2019
New Drug Application
AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
Aveo Oncology
PR-M09-18-NI-029Sep 12, 2018
Biosimilar
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer
JHL Biotech
PR-M09-18-NI-013Sep 06, 2018
Oncology
CivaTech Oncology, Inc. Offers New Technology to Fight Lung Cancer
CivaTech Oncology
PR-M08-18-NI-083Aug 21, 2018
Clinical Trials
Array BioPharma to Present Overall Survival Results from the Phase 3 LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients
LUNGevity Foundation
PR-M06-18-NI-062Jun 20, 2018
Study Results
Phase III IMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped Against Lung Cancer
Genentech
PR-M05-18-NI-116May 31, 2018
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival for Squamous Non-Small Cell Lung Cancer (NSCLC)
Merck & Co.
PR-M05-18-NI-097May 25, 2018
Clinical Data
Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO
Regeneron
PR-M05-18-NI-075May 21, 2018